CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
需要时的 PET：迈向首次复发 DLBCL 的早期 PET 适应性治疗
英文原题：A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse.
查看英文原题
A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
挽救性化疗和自体干细胞移植仍是弥漫性大B细胞淋巴瘤（DLBCL）首次复发时的标准治疗。然而，这一范式正日益受到新型免疫疗法的挑战，例如CAR-T 细胞（CAR-T 细胞）。传统的基于正电子发射断层扫描（PET）的预后评估在挽救治疗后、自体干细胞移植（ASCT）前进行，虽然有用，但对许多患者而言，这一信息来得太晚，且以不必要的毒性为代价。在本期《Leukemia & Lymphoma》中，两个研究团队展示了关于早期定量PET标志物使用及其与接受二线挽救性化疗患者结局相关性的研究结果。这些方法有望更好地识别注定治疗失败的患者，并有助于指导替代疗法的适当排序或PET适应性临床试验的开展。
展开英文摘要原文
Salvage chemotherapy and autologous stem cell transplant remain a standard of care in the management of diffuse large B cell lymphoma (DLBCL) at first relapse.
However, this paradigm is increasingly being challenged by novel immunotherapies, such as chimeric antigen receptor T-cells (CART-cells). Traditional positron emission tomography-based (PET) prognostication takes place after salvage and before autologous stem cell transplant (ASCT), and while useful, for many patients this information comes too late and at the expense of unnecessary toxicity.
In this edition of Leukemia & Lymphoma, two groups present their findings on the use of early quantitative PET markers and the correlation with outcomes in patients embarking on second line salvage chemotherapy. These approaches have the potential to better identify patients who are destined for treatment failure and help guide appropriate sequencing of alternative therapies or the development of PET-adapted clinical trials.
论文信息
- 作者
- Minson A、Hofman M、Dickinson M
- 单位
- Department of Clinical Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.Australia
- 期刊
- Leukemia & lymphoma2022 Jan
- 原文标识
- PubMed 34915805 · DOI 10.1080/10428194.2021.2015345